ES2111559T3 - Diseño y construccion de mutantes retrovirales humanos, no infecciosos, deficientes en arn genomico. - Google Patents
Diseño y construccion de mutantes retrovirales humanos, no infecciosos, deficientes en arn genomico.Info
- Publication number
- ES2111559T3 ES2111559T3 ES91900636T ES91900636T ES2111559T3 ES 2111559 T3 ES2111559 T3 ES 2111559T3 ES 91900636 T ES91900636 T ES 91900636T ES 91900636 T ES91900636 T ES 91900636T ES 2111559 T3 ES2111559 T3 ES 2111559T3
- Authority
- ES
- Spain
- Prior art keywords
- retroviruses
- infectability
- xxxx
- infectious
- found
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 230000002458 infectious effect Effects 0.000 title abstract 2
- 238000010276 construction Methods 0.000 title 1
- 230000002950 deficient Effects 0.000 title 1
- 230000001177 retroviral effect Effects 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 108010076039 Polyproteins Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000002699 waste material Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
ESTA INVENCION DEFINE UN ROL BIOLOGICO PARA LA SIGUIENTE SECUENCIA DE AMINO ACIDOS QUE SE ENCUENTRA EN EL DOMINIO NUCLEOCAPSIDO DE LAS POLIPROTEINAS PRECURSORAS "GAG" DE TODOS LOS RETROVIRUS COMPETENTES DE REPLICA: -CYS-X-X-CIS-X-X-X-X-HIS-X-X-X-X-CIS-, DONDE X REPRESENTA AMINO ACIDOS VARIABLES. LOS RESIDUOS INVARIANTES CONSTITUYEN PARTE DE UNA ESTRUCTURA DE PROTEINA VITAL, AL MENOS UNO DE LOS CUALES SE ENCUENTRA EN TODOS LOS RETROVIRUS Y ESTAN INVOLUCRADOS EN LA SELECCION Y EMPAQUETAMIENTO DE ARN VIRAL GENOMICO EN PARTICULAS DE VIRUS INFECCIOSOS. LA INTERRUPCION DE ESTA ESTRUCTURA LLEVA A LA FORMACION DE PARTICULAS TIPO-VIRUS QUE PARECEN DE ESTRUCTURA NORMAL, PERO QUE NO CONTIENEN EL COMPLEMENTO NORMAL DE ARN VIRAL. SIN EMBARGO, SU INFECTABILIDAD SE REDUCE DRASTICAMENTE O SE ELIMINA COMPLETAMENTE. LA INFECTABILIDAD DE CUALQUIER RETROVIRUS, INCLUYENDO RETROVIRUS HUMANOS, Y MAS PARTICULARMENTE EL VIRUS DE INMUNODEFICIENCIA HUMANA (VIH), SE PUEDE REDUCIR DRASTICAMENTE, O ELIMINAR COMPLETAMENTE GENERANDO MUTANTES QUE CARECEN DE ALGUN O DE TODOS LOS RESIDUOS INVARIANTES REQUERIDOS PARA FORMAR LA ESTRUCTURA. ADEMAS, CUALQUIER MEDIO PARA INTERRUMPIR LAS FUNCIONES DE ESTA RED, A SU VEZ INTERRUMPIRA EL CICLO DE VINA VIRICA. ASI, CON LOS CONOCIMIENTOS PROVISTOS POR ESTA INVENCION, SE PUEDEN IDEAR REACTIVOS QUIMIOTERAPEUTICOS DIRIGIDOS HACIA ESTA RED.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42928789A | 1989-10-31 | 1989-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2111559T3 true ES2111559T3 (es) | 1998-03-16 |
Family
ID=23702610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91900636T Expired - Lifetime ES2111559T3 (es) | 1989-10-31 | 1990-10-31 | Diseño y construccion de mutantes retrovirales humanos, no infecciosos, deficientes en arn genomico. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0500791B1 (es) |
JP (1) | JPH0716420B2 (es) |
AT (1) | ATE162949T1 (es) |
AU (1) | AU636755B2 (es) |
CA (1) | CA2072125C (es) |
DE (1) | DE69032028T2 (es) |
DK (1) | DK0500791T3 (es) |
ES (1) | ES2111559T3 (es) |
GR (1) | GR3026457T3 (es) |
WO (1) | WO1991006318A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
US5532154A (en) * | 1994-03-21 | 1996-07-02 | Research Development Foundation | Mutated alpha virus |
ATE383172T1 (de) * | 1996-05-20 | 2008-01-15 | Us Gov Health & Human Serv | Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden |
AU2001276752A1 (en) * | 2000-08-08 | 2002-02-18 | The Kitasato Institute | Virus-like micrograins and process for producing the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2067778A1 (en) * | 1989-10-16 | 1991-04-17 | The Whitehead Institute For Biomedical Research | Non-infectious hiv-1 particles and uses therefor |
-
1990
- 1990-10-31 DE DE69032028T patent/DE69032028T2/de not_active Expired - Fee Related
- 1990-10-31 ES ES91900636T patent/ES2111559T3/es not_active Expired - Lifetime
- 1990-10-31 CA CA002072125A patent/CA2072125C/en not_active Expired - Fee Related
- 1990-10-31 AU AU77402/91A patent/AU636755B2/en not_active Ceased
- 1990-10-31 EP EP91900636A patent/EP0500791B1/en not_active Expired - Lifetime
- 1990-10-31 WO PCT/US1990/006231 patent/WO1991006318A1/en active IP Right Grant
- 1990-10-31 JP JP3500783A patent/JPH0716420B2/ja not_active Expired - Fee Related
- 1990-10-31 DK DK91900636.1T patent/DK0500791T3/da active
- 1990-10-31 AT AT91900636T patent/ATE162949T1/de not_active IP Right Cessation
-
1998
- 1998-03-27 GR GR980400641T patent/GR3026457T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO1991006318A1 (en) | 1991-05-16 |
AU636755B2 (en) | 1993-05-06 |
EP0500791B1 (en) | 1998-02-04 |
DE69032028T2 (de) | 1998-05-20 |
JPH0716420B2 (ja) | 1995-03-01 |
DE69032028D1 (de) | 1998-03-12 |
EP0500791A4 (en) | 1993-02-10 |
CA2072125A1 (en) | 1991-05-01 |
GR3026457T3 (en) | 1998-06-30 |
AU7740291A (en) | 1991-05-31 |
JPH04505163A (ja) | 1992-09-10 |
CA2072125C (en) | 2000-05-23 |
DK0500791T3 (da) | 1998-04-06 |
ATE162949T1 (de) | 1998-02-15 |
EP0500791A1 (en) | 1992-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE141946T1 (de) | Hiv-2-virusvarianten | |
DE69624346D1 (de) | Verbindung der struktur aminosäure-hydroxyethylamino-sulfonamide als inhibitoren der retroviralen protease | |
ATE264914T1 (de) | Antivirale proteine, dafür kodierende dna, und deren verwendung | |
NO921969L (no) | Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener | |
ES2140380T3 (es) | Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas. | |
FR2731013B1 (fr) | Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications | |
ATE165345T1 (de) | Sulfonsaeurederivate zur behandlung von viruserkrankungen | |
DE69106493D1 (de) | Sulfonische Stilbenderivate zur Behandlung von Viruserkrankungen. | |
DE3780016D1 (de) | Pharmazeutisches praeparat mit 3'-desoxythymidin-2'-en(3'-desoxy-2',3'-didehydrothymidin) zur behandlung von patienten mit retroviralen infektionen. | |
ES2111559T3 (es) | Diseño y construccion de mutantes retrovirales humanos, no infecciosos, deficientes en arn genomico. | |
DK0404625T3 (da) | Oligonukleotidsekvenser til amplifikation af genomer af retrovirus af HIV-2 og SIV-typen samt deres anvendelser til in vitro-diagnose af infektioner forårsaget af disse virus | |
KR100725637B1 (en) | Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein | |
PT975783E (pt) | "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas" | |
DE3789525T2 (de) | Das F-Protein vom AIDS-Virus enthaltender Impfstoff. | |
MY104530A (en) | Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. | |
Williams et al. | HIV-1 and HIV-2 antibodies in Nigerian populations with high-and low-risk patterns. | |
DK135588D0 (da) | Inaktivering af hiv i proteinholdige oploesninger ved hjaelp af phenoler | |
DE59100308D1 (de) | Verwendung von s-adenosylmethionin als mittel gegen virale infektionen durch retroviren. | |
DE68925191D1 (de) | Peptide mit schutzeigenschaften gegen ein pathogenes virus des hiv-typs in sensitiven zellen | |
HUP9904262A2 (hu) | Fehérjék alkalmazása retrovírus elleni szerként | |
ES2163028T3 (es) | Composiciones y metodos para detectar y tratar el sindrome de la inmunodeficiencia adquirida. | |
FR2829503B1 (fr) | Nouvelee methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih) | |
GT199900219A (es) | Moduladores de ccr5 | |
CL2004001413A1 (es) | PEPTIDOS QUE CORRESPONDEN A LOS AMINOACIDOS 635 A 673 DE LA PROTEINA TRANSMEMBRANICA gp41 DEL VIH QUE PRESENTAN ACTIVIDAD ANTI-RETROVIRAL. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 500791 Country of ref document: ES |